Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

Research output: Contribution to journalArticle

Standard

Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. / Del Prato, S; Barnett, Anthony; Huisman, H; Neubacher, D; Woerle, HJ; Dugi, KA.

In: Diabetes, Obesity and Metabolism, Vol. 13, No. 3, 01.03.2011, p. 258-267.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{560e8cd209d94e08bb620ad221e0dee1,
title = "Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial",
abstract = "Methods: This multicentre, randomized, parallel group, phase III study compared linagliptin treatment (5 mg once daily, n = 336) with placebo (n = 167) for 24 weeks in type 2 diabetes patients. Before randomization, patients pretreated with one OAD underwent a washout period of 6 weeks, which included a placebo run-in period during the last 2 weeks. Patients previously untreated with an OAD underwent a 2-week placebo run-in period. The primary endpoint was the change in HbA1c from baseline after 24 weeks of treatment. Results: Linagliptin treatment resulted in a placebo-corrected change in HbA1c from baseline of -0.69% (p <0.0001) at 24 weeks. In patients with baseline HbA1c >= 9.0%, the adjusted reduction in HbA1c was 1.01% (p <0.0001). Patients treated with linagliptin were more likely to achieve a reduction in HbA1c of >= 0.5% at 24 weeks than those in the placebo arm (47.1 and 19.0%, respectively; odds ratio, OR = 4.2, p <0.0001). Fasting plasma glucose improved by -1.3 mmol/l (p <0.0001) with linagliptin vs. placebo, and linagliptin produced an adjusted mean reduction from baseline after 24 weeks in 2-h postprandial glucose of -3.2 mmol/l (p <0.0001). Statistically significant and relevant treatment differences were observed for proinsulin/insulin ratio (p = 0.025), Homeostasis Model Assessment-%B (p = 0.049) and disposition index (p = 0.0005). There was no excess of hypoglycaemic episodes with linagliptin vs. placebo and no patient required third-party intervention. Mild or moderate renal impairment did not influence the trough plasma levels of linagliptin. Conclusions: Monotherapy with linagliptin produced a significant, clinically meaningful and sustained improvement in glycaemic control, accompanied by enhanced parameters of beta-cell function. The safety profile of linagliptin was comparable with that of placebo.",
keywords = "glycaemic control, monotherapy, DPP-4 inhibitor, dipeptidyl peptidase-4, type 2 diabetes, linagliptin",
author = "{Del Prato}, S and Anthony Barnett and H Huisman and D Neubacher and HJ Woerle and KA Dugi",
year = "2011",
month = mar,
day = "1",
doi = "10.1111/j.1463-1326.2010.01350.x",
language = "English",
volume = "13",
pages = "258--267",
journal = "Diabetes, obesity & metabolism",
issn = "1462-8902",
publisher = "Wiley",
number = "3",

}

RIS

TY - JOUR

T1 - Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

AU - Del Prato, S

AU - Barnett, Anthony

AU - Huisman, H

AU - Neubacher, D

AU - Woerle, HJ

AU - Dugi, KA

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Methods: This multicentre, randomized, parallel group, phase III study compared linagliptin treatment (5 mg once daily, n = 336) with placebo (n = 167) for 24 weeks in type 2 diabetes patients. Before randomization, patients pretreated with one OAD underwent a washout period of 6 weeks, which included a placebo run-in period during the last 2 weeks. Patients previously untreated with an OAD underwent a 2-week placebo run-in period. The primary endpoint was the change in HbA1c from baseline after 24 weeks of treatment. Results: Linagliptin treatment resulted in a placebo-corrected change in HbA1c from baseline of -0.69% (p <0.0001) at 24 weeks. In patients with baseline HbA1c >= 9.0%, the adjusted reduction in HbA1c was 1.01% (p <0.0001). Patients treated with linagliptin were more likely to achieve a reduction in HbA1c of >= 0.5% at 24 weeks than those in the placebo arm (47.1 and 19.0%, respectively; odds ratio, OR = 4.2, p <0.0001). Fasting plasma glucose improved by -1.3 mmol/l (p <0.0001) with linagliptin vs. placebo, and linagliptin produced an adjusted mean reduction from baseline after 24 weeks in 2-h postprandial glucose of -3.2 mmol/l (p <0.0001). Statistically significant and relevant treatment differences were observed for proinsulin/insulin ratio (p = 0.025), Homeostasis Model Assessment-%B (p = 0.049) and disposition index (p = 0.0005). There was no excess of hypoglycaemic episodes with linagliptin vs. placebo and no patient required third-party intervention. Mild or moderate renal impairment did not influence the trough plasma levels of linagliptin. Conclusions: Monotherapy with linagliptin produced a significant, clinically meaningful and sustained improvement in glycaemic control, accompanied by enhanced parameters of beta-cell function. The safety profile of linagliptin was comparable with that of placebo.

AB - Methods: This multicentre, randomized, parallel group, phase III study compared linagliptin treatment (5 mg once daily, n = 336) with placebo (n = 167) for 24 weeks in type 2 diabetes patients. Before randomization, patients pretreated with one OAD underwent a washout period of 6 weeks, which included a placebo run-in period during the last 2 weeks. Patients previously untreated with an OAD underwent a 2-week placebo run-in period. The primary endpoint was the change in HbA1c from baseline after 24 weeks of treatment. Results: Linagliptin treatment resulted in a placebo-corrected change in HbA1c from baseline of -0.69% (p <0.0001) at 24 weeks. In patients with baseline HbA1c >= 9.0%, the adjusted reduction in HbA1c was 1.01% (p <0.0001). Patients treated with linagliptin were more likely to achieve a reduction in HbA1c of >= 0.5% at 24 weeks than those in the placebo arm (47.1 and 19.0%, respectively; odds ratio, OR = 4.2, p <0.0001). Fasting plasma glucose improved by -1.3 mmol/l (p <0.0001) with linagliptin vs. placebo, and linagliptin produced an adjusted mean reduction from baseline after 24 weeks in 2-h postprandial glucose of -3.2 mmol/l (p <0.0001). Statistically significant and relevant treatment differences were observed for proinsulin/insulin ratio (p = 0.025), Homeostasis Model Assessment-%B (p = 0.049) and disposition index (p = 0.0005). There was no excess of hypoglycaemic episodes with linagliptin vs. placebo and no patient required third-party intervention. Mild or moderate renal impairment did not influence the trough plasma levels of linagliptin. Conclusions: Monotherapy with linagliptin produced a significant, clinically meaningful and sustained improvement in glycaemic control, accompanied by enhanced parameters of beta-cell function. The safety profile of linagliptin was comparable with that of placebo.

KW - glycaemic control

KW - monotherapy

KW - DPP-4 inhibitor

KW - dipeptidyl peptidase-4

KW - type 2 diabetes

KW - linagliptin

U2 - 10.1111/j.1463-1326.2010.01350.x

DO - 10.1111/j.1463-1326.2010.01350.x

M3 - Article

VL - 13

SP - 258

EP - 267

JO - Diabetes, obesity & metabolism

JF - Diabetes, obesity & metabolism

SN - 1462-8902

IS - 3

ER -